Search Results - "Luo, M Jane"

Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids[S] by Chen, Yan Q., Pottanat, Thomas G., Siegel, Robert W., Ehsani, Mariam, Qian, Yue-Wei, Zhen, Eugene Y., Regmi, Ajit, Roell, William C., Guo, Haihong, Luo, M. Jane, Gimeno, Ruth E., van't Hooft, Ferdinand, Konrad, Robert J.

“…Angiopoietin-like protein (ANGPTL)8 has been implicated in metabolic syndrome and reported to regulate adipose FA uptake through unknown mechanisms. Here, we…”
Get full text

The dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis by Wilson, Jonathan M., Lin, Yanzhu, Luo, M. Jane, Considine, Gary, Cox, Amy L., Bowsman, Lenden M., Robins, Deborah A., Haupt, Axel, Duffin, Kevin L., Ruotolo, Giacomo

“…In a phase 2 trial of once‐weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose‐dependent insulinotropic polypeptide and…”
Get full text

Serum Lipid and Protein Changes in Healthy Dyslipidemic Subjects Given a Selective Inhibitor of p70 S6 Kinase‐1 by Leohr, Jennifer K., Luffer‐Atlas, Debra, Luo, M. Jane, DeBrota, David J., Green, Colin, Mabry, Thomas E., Suico, Jeffrey G.

“…The safety, pharmacokinetic, and pharmacodynamic effects of LY2584702, a selective inhibitor for p70 S6 serine/threonine protein kinase‐1, were evaluated in…”
Get full text

Identification of 4-Aminopyrazolopyrimidine Metabolite That May Contribute to the Hypolipidemic Effects of LY2584702 in Long Evans Diet-Induced Obese Rats by Estridge, Thomas B, Dey, Asim B, Reidy, Charles, Yu, Xiaohong, Zhang, Yuke, Hartley, Maryalice, Milligan, Paul L, Jin, Najia, Kowala, Mark C, Leohr, Jennifer K, Fretland, Adrian J, Mabry, Thomas E, Luffer-Atlas, Debra, Luo, M Jane

“…LY2584702 is an inhibitor of p70 S6 kinase-1 previously developed for the treatment of cancer. In two phase 1 trials in oncology patients, significant…”
Get more information

The dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A p ost hoc analysis by Wilson, Jonathan M., Lin, Yanzhu, Luo, M. Jane, Considine, Gary, Cox, Amy L., Bowsman, Lenden M., Robins, Deborah A., Haupt, Axel, Duffin, Kevin L., Ruotolo, Giacomo

“…Abstract In a phase 2 trial of once‐weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo, the dual glucose‐dependent insulinotropic…”
Get full text